Roberto Vieira sold $30K of Corcept Therapeutics stock
By AlphaYouPublished Form 4
Vieira Roberto Wandenkolk
Reporting filer
Roberto Wandenkolk Vieira reported selling 296 shares of Corcept Therapeutics Inc for about $30K ($100.82 a share on average). Form 4 filed Sep 18, 2026 lists 1 entry.
See the price move since this trade →
- Disclosed
- Sep 18, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Vieira Roberto Wandenkolk | 2026-09-16 | S | Sale | 296 | 100.82 | 3,946 | 2 days | Filed terms
|
Common Stock
- Owner
- Vieira Roberto Wandenkolk
- Date
- 2026-09-16
- Code
- S
- Action
- Sale
- Quantity
- 296
- Price
- 100.82
- Following holdings
- 3,946
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-09-16
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- id: F1
- transaction Shares: 296
- transaction Price Per Share: 100.82
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 3946
- id: F2
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Vieira Roberto Wandenkolk: President, Oncology.
- The filing reports a Rule 10b5-1 trading plan.
- F1: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
- F2: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Original sources
Prepared automatically from public filing data. Report a correction.